Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
“The novel data presented at AACR provide mechanistic insights into the
biological activity of our microbiome therapeutic candidates to augment
immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief
Scientific Officer and Executive Vice President at Seres. “The valuable
learnings obtained from this work have informed the development of
SER-401, which is being evaluated in combination with an
Seres presented preclinical results evaluating the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor. Results demonstrated that germ-free or antibiotic-treated mice lacking a functional gastrointestinal microbiome failed to mount an effective anti-tumor response when administered anti-PD-1 checkpoint inhibitor treatment. The response to anti-PD-1 treatment was restored by the introduction of a specific consortia of commensal bacteria rationally designed using insights from both in vivo and human microbiome signatures of response and the functional properties of specific bacterial strains in Seres’ strain library of gastrointestinal bacteria.
These data provide support for the continued development of SER-401, an
oral microbiome therapeutic candidate sourced from screened healthy
individuals who have been identified to have a microbiome bacterial
signature similar to that observed in responders to cancer
immunotherapy. The therapeutic aim of SER-401 is to modify the
microbiome of cancer patients to increase the efficacy of immunotherapy.
SER-401 is being evaluated in a Phase 1b clinical study (NCT03817125)
conducted in collaboration with
About Seres Therapeutics
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential impact of SER-401, the timing and results of any collaborations or clinical studies, Seres’ plans for pre-clinical development, and other statements that are not historical facts.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding; our limited operating
history; our unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development; our
reliance on third parties and collaborators to conduct our clinical
trials, manufacture our product candidates, and develop and
commercialize our product candidates, if approved; the success of our
leadership transition; our ability to retain key personnel and to manage
our growth; and our management and principal stockholders have the
ability to control or significantly influence our business. These and
other important factors discussed under the caption “Risk Factors” in
our Annual Report on Form 10-K filed with the
Reference
1. Sceneay,
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005350/en/
Source:
IR and PR Contact
Carlo Tanzi, Ph.D., Seres Therapeutics,
617-203-3467
Vice President, Investor Relations and Corporate
Communications
ctanzi@serestherapeutics.com